Literature DB >> 30597742

Determinants of noticeable symptom improvement despite sub-MCID change in SNOT-22 score after treatment for chronic rhinosinusitis.

Katie M Phillips1,2, Lloyd P Hoehle3, David S Caradonna1,4, Stacey T Gray1,2, Ahmad R Sedaghat1,2,4,5.   

Abstract

BACKGROUND: The minimal clinically important difference (MCID) of the 22-item Sino-Nasal Outcome Test (SNOT-22) is specific but not sensitive for identifying patients experiencing noticeable improvement in symptoms of chronic rhinosinusitis (CRS). It is unclear why some patients with less than 1 MCID change in SNOT-22 score nevertheless report noticeable improvement in their CRS symptoms.
METHODS: This investigation was a retrospective study of 247 CRS patients undergoing medical management who completed SNOT-22 surveys in 2 consecutive visits 2-12 months apart. The validated nasal, sleep, ear/facial discomfort, and emotional SNOT-22 subdomain scores were calculated. At the second visit, patients reported their global change in CRS symptoms on a 5-item transition rating scale as: "Much worse"; "A little worse"; "About the same"; "A little better"; or "Much better." Patient-reported improvement in symptoms (at least "A little better") was tested for association with changes in SNOT-22 subdomain scores.
RESULTS: In the entire cohort, patient-reported improvement in CRS symptoms was associated with improvement in all SNOT-22 subdomain scores (p < 0.001). In patients with less than 1 MCID (12 points) of change in the SNOT-22, only the nasal subdomain (adjusted odds ratio, 0.89; 95% confidence interval [CI], 0.79-0.99; p = 0.042) was associated with patient-reported improvement in CRS symptoms. Changes in none of the other SNOT-22 subdomain scores were associated with patient-reported improvement in CRS symptoms.
CONCLUSIONS: Among patients with less than 1 MCID change in the SNOT-22, improvement in only nasal symptoms-but not extranasal symptoms-of CRS is associated with those who nevertheless report improvement of their CRS symptoms.
© 2018 ARS-AAOA, LLC.

Entities:  

Keywords:  SNOT-22; ear/facial discomfort; emotional symptoms; improvement; minimal clinically important difference; minimum clinically important difference; nasal symptoms; sleep symptoms

Mesh:

Year:  2018        PMID: 30597742     DOI: 10.1002/alr.22269

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  6 in total

1.  Longitudinal improvement in nasal obstruction symptoms of chronic rhinosinusitis directly associates with improvement in mood.

Authors:  Marlene M Speth; Katie M Phillips; Lloyd P Hoehle; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-19       Impact factor: 2.503

2.  Seasonal variations in chronic rhinosinusitis symptom burden may be explained by changes in mood.

Authors:  Rehab Talat; Katie M Phillips; David S Caradonna; Stacey T Gray; Ahmad R Sedaghat
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-15       Impact factor: 2.503

3.  Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study.

Authors:  Anders Cervin; Joanne Rimmer; Agnieszka Wrobel; Yogen Abelak; Lindsay Brayton; Yina Kuang
Journal:  Int Forum Allergy Rhinol       Date:  2021-09-17       Impact factor: 5.426

4.  Dedicated Olfaction and Taste Items do not Improve Psychometric Performance of the SNOT-22.

Authors:  David T Liu; Katie M Phillips; Firas A Houssein; Marlene M Speth; Gerold Besser; Christian A Mueller; Ahmad R Sedaghat
Journal:  Laryngoscope       Date:  2022-03-30       Impact factor: 2.970

Review 5.  The value of endoscopic sinus surgery in chronic rhinosinusitis.

Authors:  Michael T Yim; Kristine A Smith; Jeremiah A Alt; Richard R Orlandi
Journal:  Laryngoscope Investig Otolaryngol       Date:  2021-01-23

6.  Annual trends in Google searches provides insights related to rhinosinusitis exacerbations.

Authors:  David T Liu; Martin Schally; Sven Schneider; Julia Eckl-Dorna; Katie M Phillips; Christian A Mueller; Ahmad R Sedaghat; Gerold Besser
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-04-20       Impact factor: 2.503

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.